ARV Supply Expected To Stabilise As Court Battle Ends

Monday, November 18, 2019

The supply of Anti Retroviral (ARV) drugs is expected to stabilise after government won a marathon court battle against one of the major suppliers, Portfolio Pharmaceuticals.

The company had cited irregularities in awarding of a tender for the supply of the drugs, after Portfolio Pharmaceuticals lost a significant share of the market to other players.

Following that, a lengthy court battle ensued, which had affected supply, with some patients receiving a weekly, rather than their monthly allocations.

Already have an active account? Log in here.

Or Sign up and get unlimited access to premium articles.

42 out of 45 bodies of Limpopo bus crash victims identified

Boikanyo Mathonsi | 11 h ago

Civil Society threatens court action over constitution amendment

Innocent Selatlhwa | 13 h ago

Coaches take jabs ahead of derby

Kabelo Boranabi | 13 h ago

Civil Society threatens Masisi with legal action

Innocent Selatlhwa | 16 h ago

Routine child vaccination imperative

The recent Vaccination Day in Motokwe, orchestrated through collaborative efforts between UNICEF, USAID, BRCS, and the Ministry of Health, underscores a commendable stride towards fortifying child health services.The painful reality as reflected by the Ministry of Health's data regarding the decline in routine immunisation coverage since the onset of the pandemic, is a cause for concern.It underscores the urgent need to address the...

The Monitor Editor | 15 April 2024

About us

Mmegi is the leading independent source of breaking news, latest news, current
affairs, Politics, Business, Sport, debates, analysis, and entertainment news in Botswana.

Explore

More